SWAV - Earnings announcements

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. "The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams," said Doug Godshall, President and Chief Executive Officer of Shockwave Medical. "Our team is looking forward to continuing our mission as part of Johnson & Johnson and to

Enhances Johnson & Johnson's Ability to Transform the Treatment Landscape for Cardiovascular Disease and Continue to Improve Patient Outcomes Extends Johnson & Johnson MedTech's Position in Highest-Growth, Innovation-Oriented Segments of Cardiovascular Intervention Accelerates Sales Growth and Accretive to Operating Margin for Both Johnson & Johnson and Johnson & Johnson MedTech Conference Call at 8:30 a.m. ET To Discuss Details of the Transaction Johnson & Johnson (NYSE:JNJ) and Shockwave Medical, Inc. (NASDAQ:SWAV) ("Shockwave") today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335

SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the same periods in 2022Initiated the full U.S. commercial launch of the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheterGranted new physician and hospital reimbursement for

SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates: Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)First Quarter 2024 Earnings – Monday, May 6, 2024 at 4:30 p.m. (ET)Second Quarter 2024 Earnings – Monday, August 5, 2024 at 4:30 p.m. (ET)Third Quarter 2024 Earnings – Monday, November 4, 2024 at 4:30 p.m. (ET) In

SANTA CLARA, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended September 30, 2023. Recent Highlights Recognized revenue of $186.0 million for the third quarter of 2023, representing an increase of 42% from the same period in 2022Announced, priced and closed an offering for convertible debt, with net proceeds of $634.4 millionIntroduced the Shockwave C2+ Coronary Intravascular Lithotripsy (IVL) catheter at the 35th Transcatheter Cardiovascular Therapeutics (TCT) annual sci

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, November 15, 2023, at 8:45 a.m. Eastern Time, Shockwave Medical management is scheduled to present at the 5th Annual Wolfe Research Healthcare Conference, which is taking place from Tuesday, November 14 - Wednesday, November 15, 2023,

SANTA CLARA, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended June 30, 2023. Recent Highlights Recognized revenue of $180.2 million for the second quarter of 2023, representing an increase of 49% from the same period in 2022As part of the Fiscal Year 2024 Medicare Hospital Inpatient Prospective Payment System (IPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) created three new coronary IVL-specific MS-DRGs, which will become effective October 1, 2023.

SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, August 9, 2023, at 3:30 p.m. Eastern Time, Shockwave Medical management is scheduled to present at the Canaccord Genuity 43rd Annual Growth Conference, which is taking place from Monday, August 7 - Thursday, August 10, 2023 at the Inter

SANTA CLARA, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2023. Recent Highlights Recognized revenue of $161.1 million for the first quarter of 2023, representing an increase of 72% from the same period in 2022Announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL Catheter following clearance by the U.S. Food and Drug Administration (FDA)Centers for Medicare & Medicaid Services (CMS), as part of the calendar year 2024 Medi

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2023 after market close on Monday, May 8, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, May 10, 2023, at 11:20 a.m. Pacific Time, Shockwave Medical management is scheduled for a fireside chat at the BofA Securities 2023 Healthcare Conference, which is taking place from Tuesday, May 9 - Thursday, May 11, 2023 at the Encore Hotel in Las

SANTA CLARA, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2022. Recent Highlights Recognized revenue of $144.0 million for the fourth quarter of 2022 and $489.7 million for the full year 2022, representing increases of 71% and 107%, respectively, from the same periods in 2021Received FDA approval for the Shockwave C2+ Coronary IVL Catheter in the United StatesGranted increased reimbursement for the Shockwave C2 Coronary IVL Cath

Neovasc's Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced it has entered into a definitive agreement to acquire Neovasc Inc. ((NASDAQ, TSX:NVCN), a company focused on the minimally invasive treatment of refractory angina. The Neovasc Reducer System is a first-of-its-kind technology to address refractory angin

SANTA CLARA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates: Fourth Quarter 2022 Earnings – Thursday, February 16, 2023 at 4:30 p.m. (ET)First Quarter 2023 Earnings – Monday, May 8, 2023 at 4:30 p.m. (ET)Second Quarter 2023 Earnings – Monday, August 7, 2023 at 4:30 p.m. (ET)Third Quarter 2023 Earnings – Monday, November 6, 2023 at 4:30 p.m. (ET) Investors in

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022. Recent Highlights Recognized revenue of $131.3 million for the third quarter of 2022, representing an increase of 102% from the same period in 2021Received FDA Clearance for the Shockwave IVL System with the Shockwave L6 Peripheral IVL CatheterReceived CE marking for the Shockwave C2+ coronary catheter in EuropeGranted reimbursement for the Shockwave C2 Coronary IVL Catheter by the

SANTA CLARA, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the third quarter 2022 after market close on Monday, November 7, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Interested parties may access live and archived webcasts of these events on the "Investors" section of the company's website at https://ir.shockwavemedical.com.   Investors interested in listening to the third quarter 2022 Shockwave Medical earnings conference

SANTA CLARA, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2022. Recent Highlights Recognized revenue of $120.7 million for the second quarter of 2022, representing an increase of 116% from the same period in 2021Shared two-year data from the Disrupt PAD III trial, which found that Shockwave IVL maintains superiority to angioplasty in calcified peripheral disease and preserves future treatment optionsReceived regulatory approval in China to market and

SANTA CLARA, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the second quarter 2022 after market close on Monday, August 8, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, August 10, 2022, at 3:00 p.m. Eastern Time, Shockwave Medical management is scheduled for a fireside chat at the Canaccord Genuity 42nd Annual Growth Conference, which is taking place from Monday, August 8 - Thursday, August 11, 2022 at the InterC

SANTA CLARA, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended March 31, 2022. Recent Highlights Recognized revenue of $93.6 million for the first quarter of 2022, representing an increase of 194% from the same period in 2021Received regulatory approval for the Shockwave C2 Coronary IVL Catheter in JapanAnnounced the global commercial availability and launch of the Shockwave M5+ peripheral IVL catheter after receiving both CE Mark and U.S. Food and Drug Administrat

SANTA CLARA, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, will report financial results for the first quarter 2022 after market close on Monday, May 9, 2022. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. On Wednesday, May 11, 2022, at 3:20 p.m. Pacific Time, Shockwave Medical management is scheduled for a fireside chat at the BofA Securities 2022 Healthcare Conference, which is taking place on Tuesday, May 10 - Thursday, May 12, 2022 at the Encore Hotel in Las Veg

SANTA CLARA, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2021. Recent Highlights Recognized revenue of $84.2 million for the fourth quarter of 2021 and $237.1 million for the full year of 2021, representing increases of 271% and 250%, respectively, from the same periods in 2020Centers for Medicare & Medicaid Services (CMS) reassigned the payment for peripheral IVL procedures performed on above the knee (ATK) arteries in the

SANTA CLARA, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates: Fourth Quarter 2021 Earnings – Thursday, February 17, 2022 at 4:30 p.m. (ET)First Quarter 2022 Earnings – Monday, May 9, 2022 at 4:30 p.m. (ET)Second Quarter 2022 Earnings – Monday, August 8, 2022 at 4:30 p.m. (ET)Third Quarter 2022 Earnings – Monday, November 7, 2022 at 4:30 p.m. (ET) Investors in

SANTA CLARA, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2021. Recent Highlights Recognized revenue of $65.2 million for the third quarter of 2021, representing an increase of 233% from the same period in 2020DISRUPT PAD III observational study results of peripheral IVL featured as a late breaking presentation at the VIVA21 conferenceFirst one-year results, a new gender analysis and an OCT analysis from the Disrupt CAD coronary IVL clinical pro

SANTA CLARA, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today announced it will report financial results for the third quarter 2021 after market close on Monday, November 8, 2021. Company management will host a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.   Investors interested in listening to the conference call may do so by dialing (866) 795-9106 for domestic callers or (470) 495-9173 for international callers, using conference ID: 9166273. A live and archived webcast

SANTA CLARA, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended June 30, 2021. Recent Highlights Recognized revenue of $55.9 million for the second quarter of 2021, representing an increase of 444% from the same period in 2020Granted approval for a Transitional Pass-Through (TPT) payment for Shockwave C2 Coronary IVL device, which became effective July 1, 2021 for procedures in the outpatient settingFeatured in three publications in the Journal of the American Coll